![Peter Chin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 5 M $ al 31/07/2026
Peter Chin is currently Chief Medical Officer & Head-Development at Denali Therapeutics, Inc. since 2025.
Education includes a doctorate from Geisel School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
DENALI THERAPEUTICS INC. 0,13 % | 10/04/2026 | 204.402 ( 0,13 % ) | 5 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DENALI THERAPEUTICS INC. | Director Técnico/Científico/I+D | 06/11/2025 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
Geisel School of Medicine
 Geisel School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
